• 1
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, Mclntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1998 to 1996. N Eng J Med 2000; 342: 605612.
  • 2
    Iwatsuki S, Starzl TE, Todo S et al. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: A survival report. Transplant Proc 1988; 20: 498504.
  • 3
    Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004; 77 (9 Suppl): S44S51.
  • 4
    Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4: 378383.
  • 5
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 6
    Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226231.
  • 7
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 8
    Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968974.
  • 9
    Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886897.
  • 10
    Wright TL, Donegan E, Hsu HH et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317322.
  • 11
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 12
    Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 13
    Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673684.
  • 14
    Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 3034.
  • 15
    Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229: 824831.
  • 16
    Hunt J, Gordon FD, Lewis WD et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens. Liver Transpl 2001; 7: 10561063.
  • 17
    Levy G, Villamil F, Samuel D et al. Results of list, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004: 77: 16321638.
  • 18
    Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 2227.
  • 19
    Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P. Liver transplantation for primary biliary cirrhosis: Influence of primary immunosuppression on survival. Transplant Proc 2005; 37: 16911692.
  • 20
    Bellamy CO, DiMartini AM, Ruppert K et al. Liver transplantation for alcoholic cirrhosis: Long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619626.